FRASNET Cohort: FGF21 Biomarker and Depressive Symptoms in Older Adults, 2017-2024

The FRASNET cohort study provides data from 52 community-dwelling older adults (median age 70, 61.5% women) collected between 2017 and 2024. Sarah Damanti authored this research, which investigates the association between circulating Fibroblast Growth Factor 21 (FGF21) levels and depressive symptoms measured by the Geriatric Depression Scale.

Use Cases

• Predicting depressive symptom scores based on baseline FGF21 biomarker levels mentioned in the description
• Analyzing longitudinal trends in biomarker levels over a 7-year period
• Training models for modest discriminatory performance (AUC=0.66) in identifying elevated depressive symptoms
• Investigating associations adjusted for age, sex, and body mass index as described in the methods

Strengths

• Longitudinal data collected over a 7-year period (2017-2024)
• Includes adjusted regression results with specific coefficients (B=0.003) and confidence intervals
• Uses a validated clinical scale (15-item Geriatric Depression Scale) for outcome measurement

Limitations

• Row count is unknown, which may limit suitability assessment
• Column-level documentation is absent; field semantics must be inferred after download
• The authors describe findings as preliminary, based on a small sample of 52 individuals

Provenance

Source

Sarah Damanti via figshare

Collection Method

Data obtained from the FRASNET cohort with longitudinal assessments; regression models adjusted for age, sex, and BMI.

Time Range

2017-2024

Freshness

Last updated 2026-04-10 05:58:47; freshness should be verified

Geography

Community-dwelling older adults (specific location not stated)